Hepatitis autoinmune inducida por drogas
DOI:
https://doi.org/10.47993/gmb.v48i2.1079Keywords:
autoantibodies, autoimmune, hepatitis, drug-induced liver injuryAbstract
Drug-induced autoimmune hepatitis (DIAIH) is a specific phenotype that can lead to the devastating outcome of acute liver failure requiring liver transplantation. Drugs implicated in DIAIH include the antimicrobials amoxicillin-clavulanate, nonsteroidal anti-inflammatory drugs, statins, and antinecrotic agents. A typical clinical scenario supporting DIAIH (drug-induced autoimmune hepatitis) includes a history of drug exposure with spontaneous resolution of liver injury after drug withdrawal and absence of relapse after rapid steroid tapering. The present clinical case is of a 56-year-old male with a history of blunt injury to the right hand, treated with amoxicillin plus clavulanate and paracetamol. He was progressing with progressive jaundice of the skin and mucous membranes, dark urine, asthenia, and weakness. He was referred to the emergency department of the IGBJ Hospital in Cochabamba, where an altered liver function test was found, with an autoimmune profile with anti-smooth muscle antibodies (ASMA) and elevated IgG immunoglobulin. A liver biopsy was performed, which showed: chronic hepatitis with dense portal lymphoplasmacytic infiltrate, moderate interface hepatitis or necrosis (bite-out necrosis), mild periportal fibrosis, hepatocyte and canalicular cholestasis, and fibrosis: F0 (-) malignancy. A diagnosis of autoimmune hepatitis was made. Corticosteroid treatment was started with satisfactory clinical and laboratory results.
Metrics
References
Kalliopi Z, Nikolaos K, George K. Hepatitis autoinmune, una enfermedad con múltiples caras: Características etiopatogénicas, clínico-laboratorio e histológicas. World J Gastroenterol. 2015 Jan 7;21(1):60-83. doi:10.3748/wjg.v21.i1.60 DOI: https://doi.org/10.3748/wjg.v21.i1.60
Andrade RJ, Aithal GP, de Boer YS, et al. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): an expert opinion meeting report. J Hepatol. 2023;79(3):853-66. doi:10.1016/j.jhep.2023.04.033 DOI: https://doi.org/10.1016/j.jhep.2023.04.033
Henegan MA. Hepatitis autoinmune: Patogénesis. In: UpToDate [Internet]. 2025 [cited 2024 Aug 23]. Available from: https://www.uptodate.com
Manchame R, Borrayo C. Hepatitis autoinmune inducida por drogas: asociación con nitrofurantoína. Rev Esp Casos Clin Med Intern. 2024 Dec;9(3):130-3. doi:10.32818/reccmi.a9n3a8 DOI: https://doi.org/10.32818/reccmi.a9n3a8
Heneghan MA, Lohse AW. Update in clinical science: Autoimmune hepatitis. J Hepatol. 2025 May;82(5):926-937. doi: 10.1016/j.jhep.2024.12.041. DOI: https://doi.org/10.1016/j.jhep.2024.12.041
Marino MP. Hepatitis Autoinmune. Acta Gastroenterol Latinoam. 2023;53(1):28-37.
doi: 10.52787/agl.v53i1.309 DOI: https://doi.org/10.52787/agl.v53i1.309
Covelli C, Sacchi D, Sarcognato S, et al. Pathology of autoimmune hepatitis. Pathologica. 2021;113(3):185-93. doi:10.32074/159-951X-241 DOI: https://doi.org/10.32074/1591-951X-241
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Gaceta Médica Boliviana

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2025-09-10
Published 2025-09-10